Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study
2021 · BMC Infectious Diseases · 55 citations
https://doi.org/10.1186/s12879-021-05773-w
A
Andrew Ip
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
177
Papers
1.5K
Citations
17
h-index
23
i10-index
Andrew Ip is an academic researcher from Hackensack University Medical Center. The author has contributed to research in topics: CAR-T cell therapy research & Lymphoma Diagnosis and Treatment & Cancer Genomics and Diagnostics. The author has an h-index of 17, co-authored 151 publications.
ORCID: 0000-0003-0456-5618Papers by this author
worksAn inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma
2025 · Nature Medicine · 29 citations
https://doi.org/10.1038/s41591-025-03532-x
Phase 1b dose-finding study of rituximab, lenalidomide, and ibrutinib (R2I) in patients with relapsed/refractory mantle cell lymphoma
2023 · Leukemia & lymphoma/Leukemia and lymphoma · 2 citations
https://doi.org/10.1080/10428194.2023.2259528
The clinical applications of next-generation sequencing and ctDNA/cfDNA in lymphoma.
2026 · PubMed · 0 citations
Real-world outcomes after CAR T versus standard therapy in third-line or later relapsed or refractory follicular lymphoma in the United States
2026 · Future Oncology · 0 citations
https://doi.org/10.1080/14796694.2026.2633443
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat